Lupo, V.; García-García, F.; Sancho, P.; Tello, C.; García-Romero, M.; Villarreal, L.; Alberti, A.... (2016). Assessment of Targeted Next-Generation Sequencing as a Tool for the Diagnosis of Charcot-Marie-Tooth Disease and Hereditary Motor Neuropathy. Journal of Molecular Diagnostics. 18(2):225-234. https://doi.org/10.1016/j.jmoldx.2015.10.005
Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/201210
Título:
|
Assessment of Targeted Next-Generation Sequencing as a Tool for the Diagnosis of Charcot-Marie-Tooth Disease and Hereditary Motor Neuropathy
|
Autor:
|
Lupo, Vincenzo
García-García, Francisco
Sancho, Paula
Tello, Cristina
García-Romero, Mar
Villarreal, Liliana
Alberti, Antonia
Sivera, Rafael
Pascual-Pascual, Samuel I.
Márquez-Infante, Celedonio
Casasnovas, Carlos
Sevilla, Teresa
Espinós-Armero, Carmen Ángeles
|
Entidad UPV:
|
Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural
|
Fecha difusión:
|
|
Resumen:
|
[EN] Charcot-Marie-Tooth disease is characterized by broad genetic heterogeneity with >50 known disease-associated genes. Mutations in some of these genes can cause a pure motor form of hereditary motor neuropathy, the ...[+]
[EN] Charcot-Marie-Tooth disease is characterized by broad genetic heterogeneity with >50 known disease-associated genes. Mutations in some of these genes can cause a pure motor form of hereditary motor neuropathy, the genetics of which are poorly characterized. We designed a panel comprising 56 genes associated with Charcot-Marie-Tooth disease/hereditary motor neuropathy. We validated this diagnostic tool by first testing 11 patients with pathological mutations. A cohort of 33 affected subjects was selected for this study. The DNA382 c.352+1G>A mutation was detected in two cases; novel changes and/or variants with low frequency (<1%) were found in 12 cases. There were no candidate variants in 18 cases, and amplification failed for one sample. The DNAJB2 c.352+1G>A mutation was also detected in three additional families. On haplotype analysis, all of the patients from these five families shared the same haplotype; therefore, the DNAJ82 c.352+1G>A mutation may be a founder event. Our gene panel allowed us to perform a very rapid and cost-effective screening of genes involved in Charcot-Marie-Tooth disease/hereditary motor neuropathy. Our diagnostic strategy was robust in terms of both coverage and read depth for all of the genes and patient samples. These findings demonstrate the difficulty in achieving a definitive molecular diagnosis because of the complexity of interpreting new variants and the genetic heterogeneity that is associated with these neuropathies.
[-]
|
Palabras clave:
|
Charcot-Marie-Tooth disease
,
Hereditary motor neuropathy
,
Next generation sequencing
,
Genetic testing
,
Molecular diagnosis
|
Derechos de uso:
|
Reserva de todos los derechos
|
Fuente:
|
Journal of Molecular Diagnostics. (eissn:
1525-1578
)
|
DOI:
|
10.1016/j.jmoldx.2015.10.005
|
Editorial:
|
Elsevier
|
Versión del editor:
|
https://doi.org/10.1016/j.jmoldx.2015.10.005
|
Código del Proyecto:
|
info:eu-repo/grantAgreement/MINECO//CPII14%2F00002/ES/CPII14%2F00002/
info:eu-repo/grantAgreement/MINECO//PI12%2F00453/ES/Investigación traslacional y mecanismos de enfermedad en neuropatías periféricas hereditarias/
info:eu-repo/grantAgreement/ISCIII//IR11%2FTREAT-CMT//Translational Research, Experimental Medicine and Therapeutics on Charcot-Marie-Tooth disease /
info:eu-repo/grantAgreement/ISCIII//PI12%2F00453//Investigación traslacional y mecanismos de enfermedad en neuropatías periféricas hereditarias/
info:eu-repo/grantAgreement/ISCIII//CPII14%2F00002/
|
Agradecimientos:
|
Supported by grants IR11/TREAT-CMT (C.E., CC., CM.-I., S.I.P.-P.) and PI12/00453 (C.E.) from the Institute de Salud Carlos III (ISCII)-Subdireccion General de Evaluation y Fomento de la Investigacion within the framework ...[+]
Supported by grants IR11/TREAT-CMT (C.E., CC., CM.-I., S.I.P.-P.) and PI12/00453 (C.E.) from the Institute de Salud Carlos III (ISCII)-Subdireccion General de Evaluation y Fomento de la Investigacion within the framework of the National R + D + I Plan, cofunded by the European Regional Development Fund. This collaborative joint project was awarded by the International Rare Diseases Research Consortium. C.E. has a "Miguel Servet" contract funded by grant CPII14/00002 from the ISCII and the Centro de Investigacion Principe Felipe (CEPF). The Centro de Investigacion Biomedica en Red de Enfermedades Raras is an initiative of the ISCIII.
[-]
|
Tipo:
|
Artículo
|